Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis. 2018;66(8):1290-1297.

Patel N, Cricco-Lizza E, Kasabwala K, Xu C, Robinson BD, Khani F, et al. The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy. Eur Urol Oncol. 2018;1(4):263-267.

Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H. BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO Precis Oncol. 2018;2.

Viswanathan K, Sung S, Facey KT, Alperstein SA, Pisapia DJ, Rao RA, et al. Fine needle aspiration of meningioma: Cytologic features on ThinPrep. Diagn Cytopathol. 2018;46(1):98-100.

Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, et al. Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Mol Ther Nucleic Acids. 2018;13:334-346.

Zhang W, Shu Q, Zhao Z, Fan J, Lyon CJ, Zelazny AM, et al. Antigen 85B peptidomic analysis allows species-specific mycobacterial identification. Clin Proteomics. 2018;15:1.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, Van Besien K, et al. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leuk Lymphoma. 2018;59(1):256-258.

Avecilla ST, Goss C, Marionneaux SM, Wright DR, Leiva TD, Tonon J-, et al. Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE). Adv Cell Gene Ther. 2018;1(2).

Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamò A, et al. Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Res. 2018;78(13):3413-3420.

Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, et al. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018;2(24):3618-3626.